YOLFTbeta
Laboratorios Richmond SACIF

Laboratorios Richmond SACIF

RICH · BA · Healthcare / Drug Manufacturers - Specialty & Generic

1,405.00ARS+40.00 (+2.93%)

Price History

Full chart

Market Stats

Previous Close1,365.00
Open1,405.00
Day Range1,370.00 – 1,410.00
52-Week Range1,060.00 – 2,215.00
Volume9.06K
Market Cap122.34B
P/E (TTM)8.63
Forward P/E0.00
EPS175.64
Dividend Yield2.36%
Beta-0.63
50-Day Avg1,534.50
200-Day Avg1,662.70

About

Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East. It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, antipsychotics, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company was incorporated in 1959 and is headquartered in Buenos Aires, Argentina.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOJuan Manuel Artola
  • Employees0
  • HeadquartersBouchard 680, Buenos Aires, Argentina, Argentina
  • Websitehttps://www.richmondlab.com

Leadership

  • Juan Manuel ArtolaCEO & Director
  • Ruben Jorge AlvarezChief Financial Officer
  • R.A. Patricio CarballesVP of Legal Affairs & Director
  • Norberto Pablo Garcia SantallinExecutive VP & Director

Financials

Income Statement

Currency: ARS2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue55.06M77.19M69.72M122.16M111.81M166.23M249.01M259.75M341.74M446.41M855.98M982.22M1.82B3.90B6.18B16.62B18.47B84.99B120.75B126.73B
Growth (%)-+40.19%-9.67%+75.20%-8.47%+48.67%+49.80%+4.31%+31.56%+30.63%+91.75%+14.75%+84.99%+114.37%+58.69%+168.80%+11.16%+360.14%+42.08%+4.95%
Cost of Revenue38.59M46.81M46.22M81.74M65.55M94.03M131.90M135.74M171.82M199.72M389.00M463.52M1.01B2.00B3.17B11.69B9.74B40.23B54.95B48.53B
Gross Profit---------246.70M466.98M518.69M804.91M1.89B3.01B4.93B8.73B44.76B65.80B78.19B
Gross Margin---------55.26%54.56%52.81%44.30%48.55%48.73%29.67%47.25%52.66%54.49%61.70%
Operating Expense---------153.65M227.84M348.24M675.82M1.09B1.50B2.61B5.68B33.23B44.37B44.92B
Operating Income2.34M10.45M2.19M12.34M12.13M18.20M29.36M37.71M50.02M93.04M239.14M170.45M129.09M796.51M1.51B2.32B3.04B11.53B21.44B33.27B
Operating Margin4.25%13.53%3.14%10.10%10.85%10.95%11.79%14.52%14.64%20.84%27.94%17.35%7.10%20.45%24.47%13.98%16.48%13.57%17.75%26.26%
EBITDA-----------128.75M-88.56M488.63M1.21B2.51B2.96B-13.68B56.18B33.64B
EBITDA Margin-----------13.11%-4.87%12.54%19.52%15.09%16.04%-16.10%46.52%26.54%
Net Income---------5.83M94.80M40.76M-215.60M116.44M486.24M591.46M163.43M-23.63B31.37B3.09B
Net Income Margin---------1.31%11.07%4.15%-11.87%2.99%7.87%3.56%0.88%-27.80%25.98%2.44%
R&D-1.91M60.00K102.00K-793.00K731.00K-------------
R&D as % of Total Revenue-2.47%0.09%0.08%-0.48%0.29%-------------
Interest Expense00000000000067.47M141.32M279.71M744.86M1.43B11.56B9.01B14.97B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.71%3.63%4.53%4.48%7.75%13.60%7.46%11.81%

Balance Sheet

Currency: ARS2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets56.36M77.58M100.63M127.84M135.78M159.03M270.95M287.37M385.66M532.83M861.13M1.55B2.71B5.13B8.13B25.69B40.72B337.32B342.23B420.30B
Total Liabilities48.61M64.33M71.34M74.11M90.96M108.92M178.94M196.34M292.64M436.71M671.67M864.59M1.59B3.03B4.75B20.32B30.50B287.34B256.26B327.26B
Total Equity7.75M13.24M29.29M53.73M44.81M50.11M91.95M91.04M93.02M56.79M150.13M688.05M1.05B2.05B3.38B5.29B10.09B49.10B84.58B91.50B
Cash3.47M6.11M6.52M--12.99M3.38M83.47M4.59M16.44M16.20M537.98M501.12M217.15M493.83M4.67B1.26B1.39B9.23B10.85B
Net Debt-------------279.55M1.07B12.99B20.00B36.70B179.30B214.85B

Cash Flow

Currency: ARS2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow12.87M6.73M-1.25M8.30M3.51M---25.42M-3.67M11.18M-182.16M121.02M-181.33M7.27B-4.29B-4.54B7.40B1.87B
Investing Cash Flow---------7.95M-46.46M-120.57M-260.01M-676.78M-1.06B-11.76B-7.44B---
Financing Cash Flow15.00K3.62M15.26M19.12M3.92M2.85M69.26M26.15M44.21M57.06M869.67M25.99M30.39M1.70B17.77B1.31B---
Capital Expenditure12.20M7.42M2.22M1.58M15.90M9.37M12.11M8.16M7.10M10.84M76.68M243.83M378.66M561.43M10.32B6.69B27.26B11.59B54.33B
Free Cash Flow-----------42.88M-371.56M-360.73M-716.66M-2.19B-11.80B-31.80B-4.19B-52.46B
Dividends Paid--824.00K2.54M1.18M1.03M1.58M-1.46M1.46M40.07M21.09M134.99M134.99M134.99M508.76M--2.63B
FCF to OCF-----------383.66%203.97%-298.08%395.22%-30.17%275.45%699.77%-56.68%-2811.33%
Dividend Paid to FCF-----------93.46%-5.68%-37.42%-18.84%-6.15%-4.31%---5.01%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020May 12, 2021Nov 11, 2021May 11, 2022Aug 10, 2022Nov 9, 2022Mar 31, 2023
EPS Estimate------------
EPS Actual-0.850.020.32-0.240.621.65-1.23-0.962.775.80-2.150.93
Surprise------------
Timing--------Pre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap122.34B
Enterprise Value363.99B
Trailing P/E8.63
Forward P/E0.00
Price / Sales1.07
Price / Book1.06
EPS175.64
Book Value1,459.38
Revenue (TTM)114.02B
Gross Profit (TTM)70.68B
EBITDA18.27B
Profit Margin10.97%
Operating Margin2.90%
Return on Equity13.21%
Return on Assets2.90%
Shares Outstanding66.58M
Shares Float14.17M
Beta-0.63
Dividend Yield2.36%
Dividend Rate32.61
Payout Ratio18.57%

Dividends

20221×
1.62May 9, 2022
20211×
0.55May 11, 2021
20181×
0.13May 8, 2018